Recently, Kexing Pharma have reached a strategic cooperation with Shanghai Thousand Oaks Biopharmaceutical Co., Ltd. (hereinafter referred to as "Thousand Oaks Bio") to jointly develop the KXBS001 biosimilar, officially entering the European and American biosimilars market.

The European Medicines Agency (EMA) recently released a draft plan to streamline the review process for biosimilar drug development, potentially opening a "fast track" to the EU market for domestic pharmaceutical companies. According to an IQVIA research report, the EU, as the world's leading biosimilar market (accounting for approximately 40% of its value), will have no corresponding biosimilars in development for approximately 71% of original biosimilars whose patents expire between 2024 and 2030, presenting a significant market opportunity.

Kexing Pharma adheres to the "innovation + internationalization" strategy and has formed full-chain innovation capabilities for its antibody technology platform, with a portfolio of more than ten new drugs in the fields of antiviral, tumor, and autoimmune diseases.

At the signing ceremony, Luo Shun, Chairman of Thousand Oaks Biotech, said: " Sinovac has made rapid progress on its internationalization path in recent years. Thousand Oaks Biotech will leverage its own advantages, a global vision and cutting-edge technologies to accelerate the research and development of cooperative projects."

Deng Xueqin, Chairman of Kexing Pharma, said that the Thousand Oaks Biotech team has extensive experience in CMC development, commercial production, and application for large molecules such as monoclonal antibodies, polyclonal antibodies, and ADCs. The two parties will work closely together in the future to develop high-quality biosimilars that meet the regulatory standards of China, the United States, and Europe, enrich the company's European and American product lines, and seize market opportunities.

https://finance.eastmoney.com/a/202509153514033831.html